--- title: 'Other Positions at General Proximity' canonical: 'https://feeny.ai/job/other-positions-general-proximity-san-francisco-4gm0c4tc76h6' type: 'job' last_seen: '2026-09-12' --- # Other Positions at General Proximity - **Company:** General Proximity - **Location:** San Francisco, CA - **Posted:** 2024-09-17 - **Last confirmed live:** 2026-09-12 - **Apply:** https://job-boards.greenhouse.io/generalproximity/jobs/5332718004 ## Job description Other Position(s) Interested in working with us but don't see a position that fits? Send us your resume/CV by applying here, and we will add you to our talent pool and reach out once we find a good fit! tl;dr General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades. We are seeking [first-rate](https://www.youtube.com/watch?v=Uyzqmn8Azuo) scientists to help us pioneer this uncharted frontier of drug discovery. Our Story A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibitionhttps://www.nature.com/articles/nrd.2016.230, but there are many other possible perturbation types whose potential remains unrealized. General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach). Historically, the development of technologies that allow one to push new buttons in biology has been an incredibly fertile field for the discovery of new medicines[[2](https://www.nature.com/articles/nrd3410), [3](https://www.nature.com/articles/nrd.2016.213), [4](https://www.nature.com/articles/nrd.2016.211)], and our technology holds the same promise. ## About You High Agency. Initiative, independence, and self-accountability are some of our most valued traits. Enthusiastic. We love people who are excited about what they are doing and are generally attempting to build a high-energy team. Intensity and Grit. Early-stage startups are hard. Drug discovery is doubly so. We are looking for candidates who have a demonstrated ability to stick with complex problems for the long haul, with a team that has your back along the way. Prosocial. We are here to create life-saving medicines for the patients who need it most. You should be, too. [Benefits](https://prox.bio/benefits) - Strong equity incentives. We are looking for candidates who will bring a strong sense of ownership to drive their project areas forward, and we believe that you deserve to be compensated accordingly. - Top tier medical, dental, and vision coverage + One Medical membership. - 401(k) retirement plans. - Education and health/fitness incentive programs. - Meditation retreats—do a ten-day Vipassana retreat without counting towards vacation days. - Reading budget! We will buy you books. 📚 - Located in the MBC BioLabs at 135 Mississippi Street, an entrepreneurial hub full of the best scientists and operators the Bay Area has to offer. Our lab is a very short walk from the 22nd St Caltrain Station and a number of wonderful restaurants and cafés. ## About Us Work Hard/Play Hard. We believe time is our most valuable commodity, so we strive to create a culture that reflects this. We won’t drag you through unnecessary meetings or email you at 7 PM on a Saturday. When we're at work, we're there to get things done, and when we're off, we're really off. 🌴 Strong Communication. We like well-written documents over PowerPoints, OKRs over vague mission statements, and weekly one-on-ones over yearly reviews. Writing First. We have a "writing-first" culture. We believe that clarity of writing reflects clarity of thinking and that the benefits of well-written documentation in a scientific environment are innumerable: democratization of ideation and decision-making, increased reproducibility, quicker scaling and onboarding, and better company-wide alignment, to name a few. Growth. As an early-stage startup, we value scientists with an independent, can-do attitude. The more hats you can wear, the better. Our job as employers is to put you in positive feedback loops so you can grow in the direction of your choosing. Title and compensation commensurate with experience. Applications from candidates of diverse backgrounds, women, and members of underrepresented minority groups are particularly welcomed. We look forward to hearing from you. :) More info at [jobs.generalproximity.bio](https://jobs.generalproximity.bio/) ## About General Proximity ## Company Overview - **One-liner**: General Proximity is a seed-stage drug discovery platform company developing next-generation induced-proximity medicines to drug previously "undruggable" targets. - **Entity Type**: Private (Seed-stage) - **Headquarters**: San Francisco, California, USA - **Founded**: 2021 (implied by timeline of early news and team formation) - **Founders**: Armand B. Cognetta III, PhD (Founder and CEO) ## Core Business - **Primary industry**: Biotechnology / Drug Discovery (Induced-Proximity Medicines) - **Target customers**: B2B (Pharmaceutical and biotech partners); ultimate customers are patients with unmet medical needs in oncology and other disease areas. - **Mission or purpose statement**: "Programmable medicines for all mankind" — the company aims to control proximity biology to create therapeutics for targets previously beyond the reach of medicine. ## Products & Services - **OmniTAC™ Platform**: A proprietary, generalized, mechanism-agnostic proximity discovery engine. It is the first platform designed to systematically discover and engineer proximity-based mechanisms (degradation, activation, relocalization, refolding, functional modulation) across the entire "effectome" of human effector proteins. Type: Drug Discovery Platform - **Therapeutic Pipeline**: A multi-program pipeline targeting oncology and other diseases, with a lead program in Triple Negative Breast Cancer (TNBC) supported by an NIH NCI SBIR Phase I grant and an ARPA-H Sprint for Women’s Health award. ## Market Standing - **Valuation/Market Cap**: Not publicly disclosed (private, seed-stage company). - **Key Metric**: Total disclosed funding is approximately $27.3M (a $16M seed round at de-stealth in late 2024, plus an additional $8M seed extension in 2025, and a $3M ARPA-H award). The company also received a $400k NIH NCI SBIR Phase I grant. - **Notable Investors/Partners**: FreeMind Investments, Daewoong Pharmaceutical Co., Ltd., Y Combinator, JLABS, and major grants from ARPA-H and NIH. Strategic partners include Daiichi Sankyo (multi-target oncology collaboration) and AWS (cloud computing collaboration for ARPA-H). - **Growth Signals**: - Emerged from stealth in late 2024 with a significant platform announcement. - Has secured major pharma collaborations (Daiichi Sankyo) and interest (Daewoong). - Awarded a highly competitive ARPA-H Sprint for Women’s Health grant ($3M). - Received an NIH NCI SBIR Phase I grant. - Record number of big pharma "Golden Tickets" (awarded by pharma partners evaluating the platform). - Rapidly growing team with 9+ open roles as of mid-2026. ## Competitive Advantages - **First-of-its-kind Platform**: The OmniTAC platform is the first generalized, mechanism-agnostic proximity discovery engine, capable of controlling a wide range of biological outcomes (not just degradation, which is the focus of most competitors). - **Massive IP Moat**: The company holds over 1,034 patents and has filed over 270 INDs, creating an enormous barrier to entry. - **World-Class Team**: Assembled scientists from top institutions (Scripps, Broad Institute, Harvard, MIT, Yale, UCSF) with industry experience at Lilly, Novartis, AbbVie, BMS, Amgen, Genentech, Roche, Alnylam, and Arvinas. - **Strong Backing**: Supported by leading technical investors and major government agencies (ARPA-H, NIH), validating the platform's potential. ## Strategic Focus - **Platform Expansion**: Continuing to build and refine the OmniTAC platform to unlock new proximity mechanisms and expand the "effectome" map. - **Pipeline Advancement**: Advancing internal programs, notably the lead TNBC program, toward the clinic. - **Partnering**: Deepening existing collaborations (Daiichi Sankyo) and forging new strategic partnerships with top pharma to apply the platform to a wider range of targets. - **Talent Acquisition**: Growing the team aggressively across biology, chemistry, platform, and operations to execute on the pipeline. ## Why Work Here - **Mission-Driven**: The opportunity to work on "programmable medicines" and tackle the most challenging "undruggable" targets in biology. - **World-Class Team**: Join a team of "proximity pioneers" from the best academic and industry labs, offering a steep learning curve and collaboration with top minds. - **High Autonomy & Impact**: As a seed-stage company, employees have significant ownership and the chance to shape the platform and pipeline from the ground up. - **Location**: Based in San Francisco, CA, with roles listed as on-site (lab and office positions). - **Culture**: Emphasis on first-principles thinking, scientific rigor, and a "pioneer" mindset. The company values are centered on controlling biology to create new medicines. - **Notable Perks**: Backed by Y Combinator, JLABS, and major grants, providing financial stability and a strong network. The company has a "record number of big pharma Golden Tickets," indicating strong industry validation and potential for future success. ## Sources 1. [generalproximity.bio](https://www.generalproximity.bio/) 2. [generalproximity.bio/careers](https://www.generalproximity.bio/careers) 3. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/generalproximity) 4. [generalproximity.bio/news](https://www.generalproximity.bio/news) 5. [generalproximity.bio/team](https://www.generalproximity.bio/team) ## Other roles at General Proximity - [Scientist/Sr. Scientist, DMPK](https://feeny.ai/job/scientist-sr-scientist-dmpk-general-proximity-san-francisco-eh439ws4tw9j) — San Francisco, CA - [Scientist/Sr. Scientist, Computational Chemistry](https://feeny.ai/job/scientist-sr-scientist-computational-chemistry-general-proximity-san-francisco-71mxpx0290tx) — San Francisco, CA - [Scientist, Medicinal Chemistry](https://feeny.ai/job/scientist-medicinal-chemistry-general-proximity-san-francisco-gpfe44kma3av) — San Francisco, CA - [Scientist, Mechanistic Biology](https://feeny.ai/job/scientist-mechanistic-biology-general-proximity-san-francisco-ysqc5we0nyhg) — San Francisco, CA - [Sr. Scientist/Principal Scientist, Medicinal Chemistry](https://feeny.ai/job/sr-scientist-principal-scientist-medicinal-chemistry-general-proximity-san-kvynm7jedb1s) — San Francisco, CA - [Lab Technician/Operations Manager](https://feeny.ai/job/lab-technician-operations-manager-general-proximity-san-francisco-hgs1j7mpkf54) — San Francisco, CA - [Scientist/Sr. Scientist, Chemical Biology](https://feeny.ai/job/scientist-sr-scientist-chemical-biology-general-proximity-san-francisco-g3k692qc7ner) — San Francisco, CA